1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BriaCell Therapeutics Corp. Warrant

BriaCell Therapeutics Corp. Warrant

BCTXZ
BriaCell Therapeutics Corp. WarrantUS flagNASDAQ Global Select
0.09
USD
-0.02
- -
173,493.00Market Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
- -
-8
-3
-2
-3
-4
-5
-4
-14
-27
-20
-5
-19
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
2
1
- -
1
1
1
1
-1
-4
57
41
25
-4
10
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
10
9
- -
1
1
1
1
-1
-4
28
10
-4
-3
12
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-3.98
- -
- -
- -
- -
- -
- -
- -
- -
-173.87
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
1
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'25
Total Current Assets
8
7
15
Cash, Cash Equivalents & STI
6
5
12
Accounts Receivable, Net
2
2
2
Inventories
- -
- -
- -
Total Current Liabilities
5
5
4
Payables & Accruals
5
5
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-10,376.01%
-135%
-28.92%
Free Cash Flow
86.23%
119.51%
3.53%
Net Income, GAAP
24.5%
44.44%
-76.4%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
William V. Williams
Full Time Employees
16
Sector
Healthcare
Industry
Biotechnology
Address
Bellevue Centre West Vancouver BC Canada V7T 2X1
IPO Date
Apr 25, 2025
CIK
0001610820
Website
briacell.com
Similar Companies
ChromaDex Corporation (CDXC)
Akero Therapeutics, Inc. (AKRO)
GenMont Biotech Incorporation (3164.TW)
RepliCel Life Sciences Inc. (REPCF)
KemPharm, Inc. (KMPH)
Aldeyra The (ALDX)
Business
A clinical-stage biotechnology firm, BriaCell Therapeutics Corp. focuses its efforts on pioneering innovative immunotherapies for the treatment of various cancers. The company's leading therapeutic candidate, Bria-IMT™, is an off-the-shelf, targeted cell-based immunotherapy currently undergoing a pivotal Phase 3 combination study for patients with metastatic breast cancer, where it has received U.S. FDA Fast Track designation. Beyond Bria-IMT™, BriaCell is advancing Bria-OTS™ and its optimized version, Bria-OTS+™, a sophisticated platform for personalized off-the-shelf immunotherapies. This platform leverages HLA-matching with premanufactured cells to treat advanced breast cancer, prostate cancer, and other solid tumors, with Bria-OTS currently in Phase 1/2 clinical studies. Additionally, through its subsidiary BriaPro Therapeutics, the company has strategically expanded into small molecule discovery, collaborating with Receptor.AI to develop AI-driven kinase inhibitors for oncology. BriaCell maintains significant alliances, including an ongoing collaboration with the National Cancer Institute for preclinical studies and a recent partnership with Memorial Sloan Kettering Cancer Center's Accelerator program to expedite the development of its Bria-OTS+ platform. Headquartered in West Vancouver, Canada, BriaCell Therapeutics Corp. is dedicated to transforming cancer care for patients facing limited treatment options.